You are here
Invokana (Canagliflozin) is a drug of the gliflozin class, used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson in the United States. It is of the SGLT2 inhibitors class used for the treatment of type 2 diabetes. Invokana works by helping the kidneys get rid of glucose from the bloodstream.
The U.S. Food & Drug Administration approved Invokana on March 29, 2013 for treatment of type 2 diabetes.
- 1. Invokana used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
- 2. Invokana works by increasing the removal of sugar by the kidneys through excretion.
Over a period of time, Invokana has been linked to aggravate certain medical conditions one of them being 'Ketoacidosis', a condition in which the body produces high levels of blood acids known as ketones. If left untreated, this condition can be fatal. Since it's launch in US markets several patients have developed ketoacidosis to the point of needing an emergency room visit or hospitalization.
Eventually, the Food and Drug Administration (FDA) issued a warning about Invokana in May 2015. According to the warning, this medication may lead to diabetic ketoacidosis.
In wake of the warning issued by FDA aggrieved patients are consulting with Attorneys to review legal options. The premise is based on the fact that the manufacturers and marketers of Invokana failed to warn patients and physicians of the increased risks of kidney failure, myocardial infarction (heart attacks), other cardiovascular issues and ketoacidosis. If the manufacturers and marketers had properly warned of the risks, patients would have been prescribed and taken a substitute medication for their diabetes, and certainly would have had their health monitored on a more routine basis for potential signs of heart issues, renal impairment, and high level of ketones.
Evidence to be looked for in potential cases
- Indication of usage Invokana in Medical and Pharmacy Records
- Duration of Invokana usage
- Complications and their treatment after Invokana intake
- Any other SGLT2 inhibitors used.
Medical Record Review and claim validation of Invokana case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.